This why we should refuse to anticoagulate atrial fibrillation in dialysis until there is a relevant RCT.
This why we should refuse to anticoagulate atrial fibrillation in dialysis until there is a relevant RCT.
@kidney_boy This study looks at warfarin. Would love to see an analysis with apixaban but I doubt there will ever be an RCT
@kidney_boy That’s why device therap for cva prophylaxis will become much more mainstream in the next 5-10 yrs. 90% reduction of cva risk with bleed risk <2% per year.
@kidney_boy But RCTs purists believe RCT results are transportable and that we shouldn’t think about effect modification. What say you in this example @ChristosArgyrop
@kidney_boy Crazy blind spot in the literature for such a consequential and common clinical scenario.